There are numerous medical conditions associated with depression, as mimics of depression or coexisting conditions. Associated neurologic conditions include epilepsy, multiple sclerosis, Alzheimer disease, Parkinson disease, cerebrovascular disease, and traumatic brain injury. Other associated conditions include human immunodeficiency virus infection or AIDS, neurosyphilis, cardiomyopathy, ischemic heart disease, heart failure, hypothyroidism, diabetes mellitus, vitamin deficiencies, parathyroid disorders, irritable bowel syndrome, collagen vascular diseases, and chronic liver disorders. ... It is reasonable to obtain basic laboratory testing when confirming the diagnosis of depression, especially in older patients, to exclude medical conditions that may mimic depression.

Screening questionnaires like the Patient Health Questionnaire 9 (PHQ-9) can produce high false-positive rates because depression is uncommon in primary care, and the diagnosis is affected by the correlation between somatic illnesses and the somatic symptoms of depression. The study notes that false positives and false negatives must be examined carefully.

Conclusion: In these settings, the PHQ-9 functions more as a general measure of symptoms or distress than as a disease-specific scale. This supports its use as a PROM for patients beyond those with major depression, including those with related diagnoses and those with comorbidities.

Family physicians who use the results of the PHQ-9 as supportive evidence for the presence of major depressive episode still should confirm the diagnosis by ruling out physical causes of depression, differentiating anxiety and physical symptoms that may mimic depression, and eliciting any history of manic episodes or bereavement that could confound the diagnosis.

Screening questionnaires like the Patient Health Questionnaire 9 (PHQ-9) can produce high false-positive rates because depression is uncommon in primary care, and the diagnosis is affected by the correlation between somatic illnesses and the somatic symptoms of depression. The study notes that false positives and false negatives must be examined carefully.

The PHQ-9, GAD-7 and PHQ-15 are brief well-validated measures for detecting and monitoring depression, anxiety and somatization. The PHQ-9 is a screening tool, not a diagnostic instrument, so results must be interpreted in the context of clinical assessment and possible alternative causes of symptoms.

Depression symptom measures that include somatic symptoms may inflate severity estimates among medically ill patients. In systemic sclerosis patients, PHQ-9 scores may include a small to moderate amount of variance from somatic symptoms that are not necessarily related to depression.

The PHQ-9 questions, although targeting depression, address symptoms that are also common in COPD. The study states that some items appear to be susceptible to impairments common in somatic diseases, and that asthma, sleep apnoea, gastrointestinal disorders, osteoporosis and arthritis were linked to increases in PHQ-9 scores.

Before making a final diagnosis, the clinician is expected to rule out physical causes of depression, normal bereavement, and history of a manic episode. This reflects the PHQ-9's role as part of a broader diagnostic evaluation rather than a stand-alone diagnosis.

There is concern that the Patient Health Questionnaire-9 depression scale may be impacted by the presence of somatic symptoms in patients with neurological conditions. Several PHQ-9 items demonstrated differential item functioning with respect to disease-specific severity, although salient impact was present in very few patients. These results suggest the PHQ-9 provides a consistent measure of depression severity among people with neurological conditions associated with somatic symptoms that overlap with depression.

In patients with chronic medical diseases, co-morbid major depressive disorder can be difficult to identify, because the symptoms of the two may overlap. The effect of symptom overlap on the performance of screening instruments for depression, such as the PHQ-9, would be that higher cut-off points are necessary to correctly identify MDD in the chronically ill than in a population with less severe illnesses. The overall effect would be that both sensitivity and specificity would decline.

Three PHQ-9 somatic symptom items (sleep problems, low energy, psychomotor agitation, or retardation) showed significant differential item functioning, with dialysis patients more likely than primary care patients with similar levels of depression severity to endorse these symptoms. This indicates that some PHQ-9 symptom items can be influenced by the underlying medical condition rather than depression severity alone.

Screening for depressive symptoms among cancer survivors is challenged by the overlap of somatic depression symptoms with symptoms of cancer and its treatment. It is well known that somatic symptoms of depression may overlap with symptoms of the illness and its treatment, increasing the risk of false-positive diagnoses.

The evidence from this study supports the reliability and validity of the PHQ-9 as a measure of depression in patients with heart failure and gastrointestinal symptoms. This is directly relevant because gastrointestinal and other somatic symptoms can overlap with depressive symptoms assessed by the PHQ-9.

A systematic review found only moderate levels of reporting or controlling for medical comorbidities. Brief measures may not be able to parse apart symptoms arising from purely medical versus purely psychiatric conditions, and greater attention to medical factors may better reflect true psychiatric illness as opposed to symptoms that better reflect medical comorbidities.

PHQ-9 is useful for screening, but not for diagnosis of “current major depressive episode” in a psychiatric specialty clinic. Among 73 positive cases for the PHQ-9 diagnostic algorithmic threshold, 34 cases (46.6%) were falsely positive for having a current major depressive episode. The DSM-IV-TR diagnoses of false-positive cases were schizophrenia, panic disorder, adjustment disorder, eating disorders, dementia, and insomnia, indicating that PHQ-9 positive screens can reflect symptoms of other psychiatric or neurological conditions.

Depressive and anxiety symptoms are prevalent in Lithuanian students, and the PHQ-9 and GAD-7 are valuable instruments for recognition of students at increased risk of mental health problems. However, due to the low specificity, the PHQ-9 and GAD-7 are more suitable for initial screening rather than diagnostic assessment. More detailed psychological evaluations for students at risk are required for an accurate clinical diagnosis and treatment purposes.

Compared with lower PHQ-9 scores, higher scores were associated with compromised physical status and chronic conditions, including gastro-oesophageal reflux disease and asthma. After adjustment, memory change, tension, shortness of breath and musculoskeletal symptoms such as backache and neck pain were related to higher PHQ-9 scores.

Studies have shown that screening instruments like the PHQ can be less accurate in samples with high psychiatric comorbidity, which could erode the accuracy of the PHQ in community mental health settings. This study suggests that the PHQ may not adequately identify anxiety and depressive disorders…Fifty percent of our sample had at least one anxiety disorder diagnosis, nearly half of whom were classified by the PHQ as healthy. A third of the cases of major depressive disorder were also missed by the PHQ.

Raising the PHQ-9 cut-point to 13 increases specificity and reduces false positives. The paper also notes that some somatic symptoms included in the PHQ-9 could potentially be confounded by antiepileptic medications, showing that non-depressive factors can contribute to PHQ-9 symptom endorsement.

Depression should not be diagnosed or excluded solely on the basis of a PHQ-9 score. Since the questionnaire relies on patient self-report, the practitioner should verify all responses.

Clinicians who use the PHQ-9 to screen should select a cut-off point that provides the best balance of their preferences and resources for sensitivity and specificity and true and false positive screens. Because PHQ-9 items include somatic symptoms such as sleep, appetite, and fatigue, which can be caused by physical illnesses, interpretation of positive screens should consider possible symptom overlap with comorbid medical conditions to avoid misclassification.

Experts view somatic symptoms among medical patients as the harbinger of depression and anxiety in the healthcare setting. Symptoms such as fatigue, sleep disturbance, appetite change, and psychomotor slowing can overlap with manifestations of medical illness, complicating interpretation of depression scales such as the PHQ-9.

Because depression, anxiety, and other mental health comorbidities often coexist with and can interfere with treatment of pain, use validated instruments to assess for these conditions and optimize treatment. When using tools that include somatic symptoms, clinicians should be aware that pain and other physical conditions can produce overlapping symptoms such as sleep disturbance or low energy, which may influence scores on depression screeners like the PHQ-9.

Many symptoms of depression and obstructive sleep apnea overlap, causing under-diagnosis of obstructive sleep apnea in depressed patients. Both conditions present with common mood symptoms, anxiety, restlessness, fatigue, and poor concentration.

Consider: differential diagnosis, particularly screening for Bipolar I and II; ... any medical conditions associated with depression (e.g., chronic obstructive pulmonary disease, migraine, multiple sclerosis, back problems, cancer, epilepsy, asthma, stroke, thyroid disease, diabetes and heart disease); and medications that mimic mood disorders.

Four of the nine PHQ-9 items assess somatic symptoms such as sleep, fatigue, appetite, and psychomotor changes, which can be elevated by medical conditions without depression. In medically complex patients, the PHQ-9 may overestimate depression because patients endorse somatic items reflecting illness rather than mood.

Symptoms of depression can exacerbate or mimic a medical condition. This chapter reviews cardiovascular, pulmonary, endocrine, gastrointestinal, hepatic, immunologic, dermatologic, and neurologic medical conditions that can mimic or exacerbate depression, as well as cancer and pain.

While the PHQ-9 addresses the need for a standard, copyright-free, and cost-free method for assessing depression, it also comes with serious caveats that physicians often overlook. Most notably, while the PHQ-9 scoring is intended to guide providers as a screening tool, they frequently rely solely on its score to make a diagnosis and prescribe medication. This approach fails to consider potential comorbidities and disorders that are crucial for a comprehensive clinical assessment, including conditions whose symptoms can mimic or exacerbate depressive symptoms.

The PHQ-9 focuses on nine criteria for depressive symptoms, many of which are non-specific (for example, changes in sleep, appetite, energy, concentration). These experiences can be caused by stress, physical illness, or other mental health conditions. As a result, elevated PHQ-9 scores may reflect general distress or the impact of other health problems rather than clinical depression alone, and should be interpreted in context.